Because targeted therapy is potentially very effective in patients with driver mutations,5, 6 current guidelines recommend that all patients with NSCLC, especially those with adenocarcinoma, are tested for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS1, BRAF, and PD‐L1.7, 8 The first‐line treatment for patients with NSCLC without driver mutations is cytotoxic chemotherapy, immune checkpoint inhibitors or a combination of both modalities. The gene discussed is ALK; the disease is adenocarcinoma.